CHEK2 and breast carcinoma: Some CHK2 missense variants, such as p.Ile157Thr and p.Ser428Phe (which received map scores of 0.3 and 1.2, respectively), have been reported to convey a modest (<1.5-fold) elevation of breast cancer risk.